Evaluate Safety and Efficacy of an OC Preparation vs Placebo for 6 Treatment Cycles in Women With Moderate Acne.
Public ClinicalTrials.gov record NCT00651469. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Multicenter, Double-Blind, Randomized, Placebo-Controlled Study to Evaluate Safety & Efficacy of Oral Contraceptive Prep., Containing Drospirenone 3 mg/Ethinyl Estradiol 20 Mcg for 6 Treatment Cycles in Women With Moderate Acne Vulgaris.
Study identification
- NCT ID
- NCT00651469
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 3
- Lead sponsor
- Bayer
- Industry
- Enrollment
- 534 participants
Conditions and interventions
Conditions
Interventions
- YAZ (DRSP 3 mg/EE 0.02 mg, BAY86-5300) Drug
- Placebo Drug
Drug
Eligibility (public fields only)
- Age range
- 14 Years to 45 Years
- Sex
- Female
- Healthy volunteers
- Accepts healthy volunteers
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Dec 31, 2002
- Primary completion
- Not listed
- Completion
- Jun 30, 2004
- Last update posted
- Dec 29, 2014
2003 – 2004
United States locations
- U.S. sites
- 27
- U.S. states
- 18
- U.S. cities
- 26
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Not listed | Birmingham | Alabama | 35209 | — |
| Not listed | Huntsville | Alabama | 35801 | — |
| Not listed | Mesa | Arizona | 85201 | — |
| Not listed | Los Angeles | California | 90010 | — |
| Not listed | San Diego | California | 92108 | — |
| Not listed | Washington D.C. | District of Columbia | 20010-2975 | — |
| Not listed | Miami | Florida | 33175 | — |
| Not listed | St. Petersburg | Florida | 33702 | — |
| Not listed | Tampa | Florida | 33607 | — |
| Not listed | Boise | Idaho | 83704 | — |
| Not listed | Chicago | Illinois | 60631 | — |
| Not listed | Indianapolis | Indiana | 46250 | — |
| Not listed | New Orleans | Louisiana | 70115 | — |
| Not listed | Wellesley | Massachusetts | 02481 | — |
| Not listed | Kansas City | Missouri | 64114 | — |
| Not listed | Albuquerque | New Mexico | 87106 | — |
| Not listed | Winston-Salem | North Carolina | 27103 | — |
| Not listed | Winston-Salem | North Carolina | 27157 | — |
| Not listed | Cincinnati | Ohio | 45230 | — |
| Not listed | Hershey | Pennsylvania | 17033-0850 | — |
| Not listed | Philadelphia | Pennsylvania | 19114 | — |
| Not listed | Warwick | Rhode Island | 02886 | — |
| Not listed | Austin | Texas | 78759 | — |
| Not listed | Dallas | Texas | 75230 | — |
| Not listed | Houston | Texas | 77024 | — |
| Not listed | San Antonio | Texas | 78229 | — |
| Not listed | Tacoma | Washington | 98405 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT00651469, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Dec 29, 2014 · Synced Jun 26, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT00651469 live on ClinicalTrials.gov.